Zacks Investment Research upgraded shares of Retrophin Inc. (NASDAQ:RTRX) from a hold rating to a buy rating in a report issued on Wednesday. Zacks Investment Research currently has $25.00 price target on the biopharmaceutical company’s stock.

According to Zacks, “Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company’s approved products include Chenodal┬«, Cholbam, and Thiola┬«, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego. “

RTRX has been the subject of several other research reports. BMO Capital Markets restated an outperform rating and set a $40.00 price target (up previously from $28.00) on shares of Retrophin in a research report on Thursday, September 8th. Leerink Swann restated a buy rating and set a $4.00 price target on shares of Retrophin in a research report on Tuesday, June 21st. Finally, JMP Securities restated an outperform rating and set a $28.00 price target on shares of Retrophin in a research report on Friday, September 9th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $28.40.

Retrophin (NASDAQ:RTRX) opened at 22.04 on Wednesday. Retrophin has a 52-week low of $11.60 and a 52-week high of $24.57. The company has a 50-day moving average price of $21.00 and a 200 day moving average price of $17.78. The stock has a market cap of $809.55 million, a price-to-earnings ratio of 8.95 and a beta of 1.02.

Retrophin (NASDAQ:RTRX) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.30. The business earned $33.30 million during the quarter, compared to the consensus estimate of $32.73 million. Retrophin had a net margin of 83.57% and a negative return on equity of 0.52%. The company’s revenue for the quarter was up 38.2% on a year-over-year basis. On average, analysts expect that Retrophin will post $0.09 earnings per share for the current year.

In other news, EVP Alvin Shih sold 8,750 shares of the company’s stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $16.24, for a total value of $142,100.00. Following the transaction, the executive vice president now directly owns 158,334 shares in the company, valued at approximately $2,571,344.16. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.41% of the stock is currently owned by insiders.

Large investors have recently added to or reduced their stakes in the company. First Mercantile Trust Co. raised its stake in shares of Retrophin by 35.4% in the second quarter. First Mercantile Trust Co. now owns 5,930 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 1,550 shares during the last quarter. BlackRock Inc. raised its stake in shares of Retrophin by 479.1% in the second quarter. BlackRock Inc. now owns 13,070 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 10,813 shares during the last quarter. Alambic Investment Management L.P. raised its stake in shares of Retrophin by 9.0% in the second quarter. Alambic Investment Management L.P. now owns 18,800 shares of the biopharmaceutical company’s stock worth $335,000 after buying an additional 1,550 shares during the last quarter. UBS Asset Management Americas Inc. raised its stake in shares of Retrophin by 71.1% in the second quarter. UBS Asset Management Americas Inc. now owns 19,500 shares of the biopharmaceutical company’s stock worth $347,000 after buying an additional 8,100 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale raised its stake in shares of Retrophin by 30.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 20,300 shares of the biopharmaceutical company’s stock worth $364,000 after buying an additional 4,700 shares during the last quarter.

About Retrophin

Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.

5 Day Chart for NASDAQ:RTRX

Receive News & Stock Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related stocks with our FREE daily email newsletter.